Buckley Kohlhauff
Chief Tech/Sci/R&D Officer presso NURIX THERAPEUTICS, INC.
Profilo
Buckley Kohlhauff is currently the Senior Vice President-Information Technology at Nurix Therapeutics, Inc. Prior to this, he held the position of Senior Director-Information Systems at Lexicon Pharmaceuticals, Inc. and Senior Director-Information Technology at Five Prime Therapeutics, Inc. He obtained his undergraduate degree from Carnegie Mellon University.
Posizioni attive di Buckley Kohlhauff
| Società | Posizione | Inizio |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2021 |
Precedenti posizioni note di Buckley Kohlhauff
| Società | Posizione | Fine |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| FIVE PRIME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formazione di Buckley Kohlhauff
| Carnegie Mellon University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Borsa valori
- Insiders
- Buckley Kohlhauff
